SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

English version Introducing SWFTCoin (SWFTC) $SWFTC: Powering SWFT Blockchain and AI Services (SWFTGPT)  SwftCoin ($SWFTC) is the native utility token driving SWFT Blockchain's AI-powered ecosystem, SWFTGPT, and the first ever AI token featured on Coinbase. SWFTGPT is also the first domain-specific LLM for crypto.  SwftCoin key features include: 50% Reduced Transaction Fees: Lower costs on all transactions. AI Service Payments: Use $SWFTC to access SWFTGPT. Tools include expert market analysis,  predictions, and intelligent trading solutions.  Membership Benefits: Unlock premium features and AI agent services within SWFTGPT. AI-Powered Swaps: Enable precise, fast cross-chain transactions and analytics. SWFT Blockchain combines AI innovation with blockchain infrastructure, simplifying crypto trading while enhancing functionality through $SWFTC.   Chinese version $SWFTC：驱动 SWFT Blockchain 和 AI 服务（SWFTGPT） SwftCoin ($SWFTC) 是 SWFT Blockchain 的原生实用代币，为其 AI 驱动的生态系统 SWFTGPT 提供支持，同时也是 Coinbase 上首个 AI 代币。SWFTGPT 也是首个专注于加密领域的特定领域大型语言模型 (LLM)。 SwftCoin 的主要功能包括： 1、50% 交易费减免：降低所有交易成本。 2、AI 服务支付：使用 $SWFTC 访问 SWFTGPT 工具，包括专家市场分析、预测以及智能交易解决方案。 3、会员权益：解锁 SWFTGPT 的高级功能和 AI 代理服务。 4、AI 驱动的闪兑：实现精准快速的跨链交易和数据分析。 SWFT Blockchain 将 AI 创新与区块链基础设施结合，通过 $SWFTC 简化加密交易，并提升其功能性。

SwftCoin

SwftCoin is seeing a surge in community discussion, with investors actively anticipating a significant price run, citing its innovative AI-integrated cross-chain utility and strong tokenomics. The bullish sentiment is further amplified by calls to collectively boost its visibility, drawing parallels to its past explosive market performances.

Moo Deng

MOODENG CRYPTO is generating significant buzz and buying interest, with the community actively discussing its potential for explosive upward movement amid a broader bullish sentiment for meme coins. Many are accumulating, citing its relatively low market cap and high trading volume as key indicators for a substantial rally.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending with its community enthusiastically anticipating a cultural and potential price surge leading into the significant "4/20" event, following a period focused on "bong-term" culture building on Solana. The discussion is split between advocates highlighting its mission to unite global cannabis culture and skeptics labeling it a pump-and-dump scheme amid broader cannabis rescheduling conversations.

Propy is a decentralized real-estate market place backed by superior blockchain infrastructure to facilitate real-time unified transaction in order to reduce fraud and redundancy. Propy is the world’s first international real-estate marketplace.

Propy

Propy is trending as the crypto community discusses its innovative approach to real estate tokenization, driven by an upcoming first on-chain property sale and a recently unveiled 2025 roadmap detailing AI integration. While many view its low market cap as ripe for growth in the Real World Assets (RWA) sector, others remain cautious, citing past price volatility and skepticism.

Bridgford Foods Corp. engages in the manufacture, market, and distribution of frozen and snack food products. It operates through the Frozen Food Products and Snack Food Products segments. The Frozen Food Products segment manufactures and distributes food products, including biscuits, bread dough items, roll dough items, and sandwiches. The Snack Food Products segment distributes both products manufactured by the company and third parties. The company was founded by Hugh H. Bridgford in February 1932 and is headquartered in Dallas, TX.

Bridgford Foods Corp.

Bridgford Foods Corporation

Bridgford Foods (BRID) is trending as the community speculates on a significant boost to its gross margins from President Trump's initiatives to lower beef prices through increased imports. Investors are also noting the company's aggressive push into private-label offerings with major retailers, viewing it as a deeply undervalued defensive play within the strengthening food sector.

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals plc

Jazz Pharmaceuticals is trending due to strong positive Phase 3 data for its cancer drug Ziihera in gastroesophageal cancer and recent FDA accelerated approval for biliary tract cancer. This success is driving significant share price gains and analyst upgrades, with the community actively discussing Ziihera's potential as a new oncology standard of care and the company's overall valuation.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIM is trending amid ongoing strategic review processes and multiple acquisition bids, notably a rejected "undervalued" offer from its CEO and interest from Hapag-Lloyd. The community is actively discussing the company's significant undervaluation and the potential for a bidding war, alongside concerns over Israeli government approval for the strategic asset.

Jack in the Box, Inc. engages in the provision of developing, operating, and franchising a chain of quick-service and fast-casual restaurants. It operates through the Jack in the Box and Del Taco segments. The Jack in the Box segment offers a selection of distinctive products including classic burgers and other product lines such as Buttery Jack Burgers. The company was founded by Robert Oscar Peterson in 1951 and is headquartered in San Diego, CA.

Jack In The Box, Inc.

Jack In The Box is trending amidst a crucial turnaround effort, driven by its announced sale of Del Taco and an activist investor's increasing stake, as the community debates significant debt concerns against the potential for a short squeeze and a successful operational recovery.

Southern Copper Corp. engages in the development, production, and exploration of copper, molybdenum, zinc, and silver. It operates through the following segments: Peruvian Operations, Mexican Open-Pit Operations, and Mexican Underground Mining Operations. The Peruvian Operations segment focuses on the Toquepala and Cuajone mine complexes and the smelting and refining plants, industrial railroad, and port facilities that service both mines. The Mexican Open-Pit Operations segment comprises the La Caridad and Buenavista mine complexes, the smelting, and refining plants and support facilities, which service both mines. The Mexican Underground Mining Operations segment is involved in the operation of five underground mines, a coal mine, and several industrial processing facilities. The company was founded on December 12, 1952 and is headquartered in Phoenix, AZ.

Southern Copper Corporation

Southern Copper is generating significant discussion amidst a record surge in copper prices, driven by expectations of massive demand from EVs, AI, and infrastructure upgrades, further amplified by its designation as a US critical mineral. While community sentiment is largely bullish, highlighting recent strong earnings, some investors are weighing concerns about its premium valuation and projected output decline in 2026.

Hudbay Minerals, Inc. operates as a mining company. The firm engages in the production of copper concentrate, molybdenum concentrate and zinc metal. It focuses on the discovery, production and marketing of base and precious metals. The company was founded on January 16, 1996 and is headquartered in Toronto, Canada.

Hudbay Minerals Inc.

Hudbay Minerals is gaining significant attention as copper prices hit record highs, driven by increasing global demand from sectors like EVs and data centers. The community is actively discussing the company's strategic Copper World project and recent strong earnings, positioning it as a major player in the tightening copper market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch

Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical...

Vaximm Appoints Sbastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform

Vaximm Appoints Sbastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform Vaximm Appoints Sbastien Wieckowski, PhD, as Chief Scientific Officer to...

Vaximm, an OSR Company, Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with $30M Upfront and Up to $815M in Milestones

Vaximm, an OSR Company, Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with $30M Upfront and Up to $815M in Milestones Vaximm, an OSR Company, Receives Binding Term...

Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings

Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings PR...

Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period to Three Months

Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period to Three Months Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period...

OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025

OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025 OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025 PR Newswire BELLEVUE, Wash., Dec. 1, 2025...

Cancer Immunotherapy Microcap Soars on Possible Major Licensing Deal

As pharmaceutical giants increasingly look outside their walls for breakthrough innovations, the licensing model has become the preferred pathway for bringing next-generation therapies to market. Biotech companies with promising platforms are commanding substantial upfront payments and milestone structures that can exceed $800 million, reflecting the pharmaceutical industry's appetite for differentiated assets that address significant unmet medical needs in oncology.Shares of OSR Holdings, Inc. (<a href="https://www.allpennystocks.com/stockquote/osrh" target="_blank">NASDAQ: OSRH</a>) are surging Friday after the company announced that its subsidiary Vaximm AG has entered a non-binding term sheet with BCM Europe AG for a potential exclusive global licensing agreement covering VXM01, Vaximm's first-in-class oral cancer immunotherapy platform.The proposed deal structure outlines significant financial terms that underscore the asset's commercial potential. Vaximm would receive a $20 million upfront payment upon execution of a definitive agreement, followed by up to $815 million in clinical, regulatory, and commercial milestone payments as the program advances through development and commercialization. Additionally, Vaximm would receive a pass-through of commercial royalties that BCME may collect from any future pharmaceutical partner, structured with a defined delta-recovery mechanism that allows BCME to recoup milestone differentials before royalty sharing commences.The term sheet establishes a six-month exclusivity period during which both parties will work toward finalizing a definitive licensing agreement, subject to customary due diligence and board approvals. Under the contemplated framework, BCME would function as a strategic financial intermediary, providing capital to fund the partnering and development activities necessary to secure a global out-license with a major pharmaceutical company. This approach mirrors structured financing models deployed by specialized life sciences investors including Royalty Pharma, Blackstone Life Sciences, and RTW Investments.According to Andreas Niethammer, incoming CEO of Vaximm AG, the term sheet represents an important milestone for advancing VXM01's development and global commercialization while allowing Vaximm to retain full ownership of its intellectual property. The structure enables the company to continue its mission of delivering innovative immunotherapies to patients worldwide with reduced dilution risk.Tim Smith, Head of Investor Relations at OSR Holdings, emphasized that Vaximm's oral T-cell platform represents a genuinely innovative approach in oncology with potential to transform cancer treatment. The exclusivity period with BCME reflects shared commitment to maximizing the global opportunity for VXM01, positioning the asset for a major pharmaceutical partnership that could unlock its full commercial potential.The term sheet also incorporates an optional blockchain-based royalty participation mechanism utilizing "TAC" tokens as an on-chain representation of future royalty revenue streams. Should Vaximm elect to draw development capital from the BCM Royalty Fund, a portion of VXM01 commercial royalties could be allocated to TAC token holders. If this option is not exercised, royalties would flow exclusively through the BCME pass-through structure.Vaximm's VXM01 platform employs a proprietary oral T-cell vaccination approach using live, attenuated bacterial vectors to deliver tumor-associated antigens and induce robust cellular immune responses. The lead candidate targets VEGFR-2 and has demonstrated clinical activity and safety across multiple cancer indications. BCME, a Switzerland-based life sciences investment entity, is currently OSR Holdings' largest shareholder.Shares of OSRH are up 25.8% at $0.57 in Friday afternoon trading. Copyright © 2025 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.View <a href='https://www.allpennystocks.com/specialreportsUS/4014/cancer-immunotherapy-microcap-soars-on-possible-major-licensing-deal'>more of this article</a> on AllPennyStocks.com.About AllPennyStocks.com Media, Inc.:
Founded in 1999, AllPennyStocks.com Media, Inc. is North America's largest and longest running website dedicated exclusively to micro-cap and small-cap insights.
Catering to both Canadian and U.S. markets, AllPennyStocks.com provides a wealth of resources and expert content designed for everyone, from beginner investors to seasoned traders.
AllPennyStocks.com's content is prominently featured across numerous top-tier financial platforms, reaching a broad audience of investors and industry professionals.
Contact:
AllPennyStocks.com Media, Inc.
Email: <a href="mailto:ads@allpennystocks.com">ads@allpennystocks.com</a>
Phone: (800) 558-4560 Ext: 101

Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones

Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe...

OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion

OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion OSR Holdings Appoints Scientific Co-Founder...

OSR Holdings Announces Woori IO's Noninvasive Glucose Monitor Demonstrates High Accuracy and Precision in Company-Sponsored Pilot Study

OSR Holdings Announces Woori IO's Noninvasive Glucose Monitor Demonstrates High Accuracy and Precision in Company-Sponsored Pilot Study OSR Holdings Announces Woori IO's Noninvasive Glucose Monitor...

OSR Holdings, Inc. operates as a global healthcare company. The firm engages in developing oral immunotherapies for cancer treatment, design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention of medical devices and systems distribution in Korea. Its products are offered through its subsidiaries. The company was founded on February 25, 2020 and is headquartered in Bellevue, WA.

OSR Holdings Inc.

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

Current Price	$0.496
Prev Close	$0.462
Open	$0.4744
Dividend Yield	0.00%
50-Day Moving Average	$0.6274
Beta	0.41
Avg. Volume	3.18M
PE Ratio	-0.25

52-Week High	$10.00
52-Week Low	$0.453
Market Capitalization	$12.73M
EPS (Annual)	-$0.5379
Price to Book	0.14
Revenue Per Employee	$0.00

OSRH
OSR Holdings Inc

Feed

News

Sentiment

Fundamentals

Info

Latest OSRH News

OSRHOSR Holdings Inc